Tina Weinzierl

Preclinical Activity of the Type II CD20 Antibody GA101 (Obinutuzumab) Compared with Rituximab and Ofatumumab <i>In Vitro</i> and in Xenograft Models

Sylvia Herter, Frank Herting, Olaf Mundigl et al. · Molecular Cancer Therapeutics · 2013 · 352 citations

Xenograft Models, Immunology, Immune Regulation +20

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

Marina Bacac, Tanja Fauti, Johannes Sam et al. · Clinical Cancer Research · 2016 · 342 citations · Full text

Human immunocompetent Organ-on-Chip platforms allow safety profiling of tumor-targeted T-cell bispecific antibodies

S. Jordan Kerns, Chaitra Belgur, Debora B. Petropolis et al. · eLife · 2021 · 69 citations · Full text

Immunology, Antigen Processing, Immune System +17

XGFR*, a novel affinity-matured bispecific antibody targeting IGF-1R and EGFR with combined signaling inhibition and enhanced immune activation for the treatment of pancreatic cancer

Juergen Schanzer, Katharina Wartha, Ekkehard Moessner et al. · mAbs · 2016 · 31 citations · Full text

Predicting Tumor Killing and T-Cell Activation by T-Cell Bispecific Antibodies as a Function of Target Expression: Combining <i>In Vitro</i> Experiments with Systems Modeling

Arthur J. Van De Vyver, Tina Weinzierl, Miro J. Eigenmann et al. · Molecular Cancer Therapeutics · 2020 · 25 citations · Full text